Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide

M. J. Kennedy, Ross C Donehower, E. K. Rowinsky

Research output: Contribution to journalArticle

Abstract

Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated substantial single-agent activity against both minimally pretreated and resistant metastatic breast cancer. Evaluation of paclitaxel- based combinations has demonstrated appreciable activity, but also toxicity, for the paclitaxel/doxorubicin combination. The paclitaxel/cyclophosphamide combination is potentially attractive because of the significant single- agent activity of both drugs against metastatic breast cancer and the paucity of shared nonhematologic toxicities. This combination is being evaluated in women with doxorubicin-refractory metastatic breast cancer. Dose escalation to paclitaxel 200 mg/m2 over 24 hours and cyclophosphamide 2,000 mg/m2 administered every 21 days with granulocyte colony-stimulating factor support has been performed. The final dose level was complicated by dose-limiting toxicity. The maximum tolerated dose for this combination is currently being defined. There is preliminary evidence of sequence-dependent toxicity. Grade 4 neutropenia and neutropenic fevers are more frequent in cycles in which paclitaxel is administered first.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalSeminars in Oncology
Volume22
Issue number4 SUPPL. 8
StatePublished - 1995

Fingerprint

Paclitaxel
Cyclophosphamide
Breast Neoplasms
Doxorubicin
Therapeutics
Maximum Tolerated Dose
Granulocyte Colony-Stimulating Factor
Neutropenia
Fever
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide. / Kennedy, M. J.; Donehower, Ross C; Rowinsky, E. K.

In: Seminars in Oncology, Vol. 22, No. 4 SUPPL. 8, 1995, p. 23-27.

Research output: Contribution to journalArticle

Kennedy, M. J. ; Donehower, Ross C ; Rowinsky, E. K. / Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide. In: Seminars in Oncology. 1995 ; Vol. 22, No. 4 SUPPL. 8. pp. 23-27.
@article{be31092a692146bf932185b254f5cbf0,
title = "Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide",
abstract = "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated substantial single-agent activity against both minimally pretreated and resistant metastatic breast cancer. Evaluation of paclitaxel- based combinations has demonstrated appreciable activity, but also toxicity, for the paclitaxel/doxorubicin combination. The paclitaxel/cyclophosphamide combination is potentially attractive because of the significant single- agent activity of both drugs against metastatic breast cancer and the paucity of shared nonhematologic toxicities. This combination is being evaluated in women with doxorubicin-refractory metastatic breast cancer. Dose escalation to paclitaxel 200 mg/m2 over 24 hours and cyclophosphamide 2,000 mg/m2 administered every 21 days with granulocyte colony-stimulating factor support has been performed. The final dose level was complicated by dose-limiting toxicity. The maximum tolerated dose for this combination is currently being defined. There is preliminary evidence of sequence-dependent toxicity. Grade 4 neutropenia and neutropenic fevers are more frequent in cycles in which paclitaxel is administered first.",
author = "Kennedy, {M. J.} and Donehower, {Ross C} and Rowinsky, {E. K.}",
year = "1995",
language = "English (US)",
volume = "22",
pages = "23--27",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 8",

}

TY - JOUR

T1 - Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide

AU - Kennedy, M. J.

AU - Donehower, Ross C

AU - Rowinsky, E. K.

PY - 1995

Y1 - 1995

N2 - Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated substantial single-agent activity against both minimally pretreated and resistant metastatic breast cancer. Evaluation of paclitaxel- based combinations has demonstrated appreciable activity, but also toxicity, for the paclitaxel/doxorubicin combination. The paclitaxel/cyclophosphamide combination is potentially attractive because of the significant single- agent activity of both drugs against metastatic breast cancer and the paucity of shared nonhematologic toxicities. This combination is being evaluated in women with doxorubicin-refractory metastatic breast cancer. Dose escalation to paclitaxel 200 mg/m2 over 24 hours and cyclophosphamide 2,000 mg/m2 administered every 21 days with granulocyte colony-stimulating factor support has been performed. The final dose level was complicated by dose-limiting toxicity. The maximum tolerated dose for this combination is currently being defined. There is preliminary evidence of sequence-dependent toxicity. Grade 4 neutropenia and neutropenic fevers are more frequent in cycles in which paclitaxel is administered first.

AB - Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated substantial single-agent activity against both minimally pretreated and resistant metastatic breast cancer. Evaluation of paclitaxel- based combinations has demonstrated appreciable activity, but also toxicity, for the paclitaxel/doxorubicin combination. The paclitaxel/cyclophosphamide combination is potentially attractive because of the significant single- agent activity of both drugs against metastatic breast cancer and the paucity of shared nonhematologic toxicities. This combination is being evaluated in women with doxorubicin-refractory metastatic breast cancer. Dose escalation to paclitaxel 200 mg/m2 over 24 hours and cyclophosphamide 2,000 mg/m2 administered every 21 days with granulocyte colony-stimulating factor support has been performed. The final dose level was complicated by dose-limiting toxicity. The maximum tolerated dose for this combination is currently being defined. There is preliminary evidence of sequence-dependent toxicity. Grade 4 neutropenia and neutropenic fevers are more frequent in cycles in which paclitaxel is administered first.

UR - http://www.scopus.com/inward/record.url?scp=0029152812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029152812&partnerID=8YFLogxK

M3 - Article

C2 - 7543700

AN - SCOPUS:0029152812

VL - 22

SP - 23

EP - 27

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 8

ER -